Cargando…

A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus

Newcastle disease (ND) is endemic in Bangladesh. Locally produced or imported live Newcastle disease virus (NDV) vaccines based on lentogenic virus strains, locally produced live vaccines of the mesogenic Mukteswar strain, as well as imported inactivated vaccines of lentogenic strains, are being use...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Ismail, Subarna, Jannatul Ferdous, Kabiraj, Congriev Kumar, Begum, Jahan Ara, Parvin, Rokshana, Martins, Mathias, Diel, Diego G., Chowdhury, Emdadul Haque, Islam, Mohammad Rafiqul, Nooruzzaman, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221827/
https://www.ncbi.nlm.nih.gov/pubmed/37243108
http://dx.doi.org/10.3390/vaccines11051005
_version_ 1785049549526532096
author Hossain, Ismail
Subarna, Jannatul Ferdous
Kabiraj, Congriev Kumar
Begum, Jahan Ara
Parvin, Rokshana
Martins, Mathias
Diel, Diego G.
Chowdhury, Emdadul Haque
Islam, Mohammad Rafiqul
Nooruzzaman, Mohammed
author_facet Hossain, Ismail
Subarna, Jannatul Ferdous
Kabiraj, Congriev Kumar
Begum, Jahan Ara
Parvin, Rokshana
Martins, Mathias
Diel, Diego G.
Chowdhury, Emdadul Haque
Islam, Mohammad Rafiqul
Nooruzzaman, Mohammed
author_sort Hossain, Ismail
collection PubMed
description Newcastle disease (ND) is endemic in Bangladesh. Locally produced or imported live Newcastle disease virus (NDV) vaccines based on lentogenic virus strains, locally produced live vaccines of the mesogenic Mukteswar strain, as well as imported inactivated vaccines of lentogenic strains, are being used in Bangladesh under different vaccination regimens. Despite these vaccinations, frequent outbreaks of ND are being reported in Bangladesh. Here we compared the efficacy of booster immunization with three different vaccines in chickens that had been primed with two doses of live LaSota vaccine. A total of 30 birds (Group A) were primed with two doses of live LaSota virus (genotype II) vaccine at days 7 and 28, while 20 birds (Group B) remained unvaccinated. At day 60, birds of Group A were divided into three sub-groups, which received booster immunizations with three different vaccines; A1: live LaSota vaccine, A2: inactivated LaSota vaccine, and A3: inactivated genotype XIII.2 vaccine (BD-C161/2010 strain from Bangladesh). Two weeks after booster vaccination (at day 74), all vaccinated birds (A1–A3) and half of the unvaccinated birds (B1) were challenged with a genotype XIII.2 virulent NDV (BD-C161/2010). A moderate antibody response was observed after the primary vaccination, which substantially increased after the booster vaccination in all groups. The mean HI titers induced by the inactivated LaSota vaccine (8.0 log(2)/5.0 log(2) with LaSota/BD-C161/2010 HI antigen) and the inactivated BD-C161/2010 vaccine (6.7 log(2)/6.2 log(2) with LaSota/BD-C161/2010 HI antigen) were significantly higher than those induced by the LaSota live booster vaccine (3.6 log(2)/2.6 log(2) with LaSota/BD-C161/2010 HI antigen). Despite the differences in the antibody titers, all chickens (A1–A3) survived the virulent NDV challenge, while all the unvaccinated challenged birds died. Among the vaccinated groups, however, 50% of the chickens in Group A1 (live LaSota booster immunization) shed virus at 5- and 7-days post challenge (dpc), while 20% and 10% of the chickens in Group A2 (inactivated LaSota booster immunization) shed virus at 3 and 5 dpc, respectively, and only one chicken (10%) in Group A3 shed virus at 5 dpc. In conclusion, the genotype-matched inactivated NDV booster vaccine offers complete clinical protection and a significant reduction in virus shedding.
format Online
Article
Text
id pubmed-10221827
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102218272023-05-28 A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus Hossain, Ismail Subarna, Jannatul Ferdous Kabiraj, Congriev Kumar Begum, Jahan Ara Parvin, Rokshana Martins, Mathias Diel, Diego G. Chowdhury, Emdadul Haque Islam, Mohammad Rafiqul Nooruzzaman, Mohammed Vaccines (Basel) Article Newcastle disease (ND) is endemic in Bangladesh. Locally produced or imported live Newcastle disease virus (NDV) vaccines based on lentogenic virus strains, locally produced live vaccines of the mesogenic Mukteswar strain, as well as imported inactivated vaccines of lentogenic strains, are being used in Bangladesh under different vaccination regimens. Despite these vaccinations, frequent outbreaks of ND are being reported in Bangladesh. Here we compared the efficacy of booster immunization with three different vaccines in chickens that had been primed with two doses of live LaSota vaccine. A total of 30 birds (Group A) were primed with two doses of live LaSota virus (genotype II) vaccine at days 7 and 28, while 20 birds (Group B) remained unvaccinated. At day 60, birds of Group A were divided into three sub-groups, which received booster immunizations with three different vaccines; A1: live LaSota vaccine, A2: inactivated LaSota vaccine, and A3: inactivated genotype XIII.2 vaccine (BD-C161/2010 strain from Bangladesh). Two weeks after booster vaccination (at day 74), all vaccinated birds (A1–A3) and half of the unvaccinated birds (B1) were challenged with a genotype XIII.2 virulent NDV (BD-C161/2010). A moderate antibody response was observed after the primary vaccination, which substantially increased after the booster vaccination in all groups. The mean HI titers induced by the inactivated LaSota vaccine (8.0 log(2)/5.0 log(2) with LaSota/BD-C161/2010 HI antigen) and the inactivated BD-C161/2010 vaccine (6.7 log(2)/6.2 log(2) with LaSota/BD-C161/2010 HI antigen) were significantly higher than those induced by the LaSota live booster vaccine (3.6 log(2)/2.6 log(2) with LaSota/BD-C161/2010 HI antigen). Despite the differences in the antibody titers, all chickens (A1–A3) survived the virulent NDV challenge, while all the unvaccinated challenged birds died. Among the vaccinated groups, however, 50% of the chickens in Group A1 (live LaSota booster immunization) shed virus at 5- and 7-days post challenge (dpc), while 20% and 10% of the chickens in Group A2 (inactivated LaSota booster immunization) shed virus at 3 and 5 dpc, respectively, and only one chicken (10%) in Group A3 shed virus at 5 dpc. In conclusion, the genotype-matched inactivated NDV booster vaccine offers complete clinical protection and a significant reduction in virus shedding. MDPI 2023-05-20 /pmc/articles/PMC10221827/ /pubmed/37243108 http://dx.doi.org/10.3390/vaccines11051005 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hossain, Ismail
Subarna, Jannatul Ferdous
Kabiraj, Congriev Kumar
Begum, Jahan Ara
Parvin, Rokshana
Martins, Mathias
Diel, Diego G.
Chowdhury, Emdadul Haque
Islam, Mohammad Rafiqul
Nooruzzaman, Mohammed
A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title_full A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title_fullStr A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title_full_unstemmed A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title_short A Booster with a Genotype-Matched Inactivated Newcastle Disease Virus (NDV) Vaccine Candidate Provides Better Protection against a Virulent Genotype XIII.2 Virus
title_sort booster with a genotype-matched inactivated newcastle disease virus (ndv) vaccine candidate provides better protection against a virulent genotype xiii.2 virus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221827/
https://www.ncbi.nlm.nih.gov/pubmed/37243108
http://dx.doi.org/10.3390/vaccines11051005
work_keys_str_mv AT hossainismail aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT subarnajannatulferdous aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT kabirajcongrievkumar aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT begumjahanara aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT parvinrokshana aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT martinsmathias aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT dieldiegog aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT chowdhuryemdadulhaque aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT islammohammadrafiqul aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT nooruzzamanmohammed aboosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT hossainismail boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT subarnajannatulferdous boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT kabirajcongrievkumar boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT begumjahanara boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT parvinrokshana boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT martinsmathias boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT dieldiegog boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT chowdhuryemdadulhaque boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT islammohammadrafiqul boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus
AT nooruzzamanmohammed boosterwithagenotypematchedinactivatednewcastlediseasevirusndvvaccinecandidateprovidesbetterprotectionagainstavirulentgenotypexiii2virus